文献速递神经肿瘤功能神经外科

岛叶胶质瘤切除术后癫痫结局:系统综述、Meta分析及本机构经验

Seizure outcome after resection of insular glioma: a systematic review, meta-analysis, and institutional experience.
PubMed 文献 · J Neurosurg · 2022-10-14

该系统综述与Meta分析纳入8项研究453例患者460次手术,汇总1年Engel IA级无癫痫发作率为73%、Engel I级为78%,末次随访分别为60%和79%;本机构109例中更大切除程度是术后无癫痫发作的唯一显著独立预测因素(HR 0.290,p=0.017),最佳阈值为切除程度81%。

要点

  • Meta分析汇总1年Engel IA级无癫痫发作率73%,末次随访降至60%。
  • 本机构109例中更大切除程度是无癫痫发作唯一显著独立预测因素(HR 0.290,p=0.017)。
  • 切除程度>81%者无癫痫发作率显著更高(OR 2.16,p=0.048)。

核心结论

  • 最大安全切除可在手术并发症极少的情况下实施,并在短期和长期获得较好的无癫痫发作率。
  • 当无法实现全切除时,切除程度>81%对实现无癫痫发作具有最大的敏感度和特异度。

研究设计与样本

  • 系统检索Ovid MEDLINE、Embase和Cochrane Central Register of Controlled Trials三个数据库,检索时间从建库至2021年3月27日,纳入已发表的岛叶胶质瘤切除术后癫痫结局研究。
  • Meta分析纳入8项研究,报告453例患者共460次手术;汇总平均年龄42岁。
  • 本机构回顾性收集1997年6月至2015年6月间所有年龄>17岁、接受岛叶胶质瘤切除的成人数据,共109例。
  • 主要结局指标为1年及末次随访时的无癫痫发作率;次要结局指标为术后持续超过90天的神经功能缺损、死亡率和肿瘤进展或复发。

主要发现

  • 汇总切除程度≥90%、70%-89%和<70%的患者百分比分别为55%、33%和11%。
  • 汇总1年无癫痫发作率:Engel IA级为73%,Engel I级为78%。
  • 汇总末次随访无癫痫发作率:Engel IA级为60%,Engel I级为79%。
  • 汇总术后持续超过90天的神经功能缺损百分比为3%。
  • 本机构109例中,更大切除程度是术后无癫痫发作的唯一显著独立预测因素(HR 0.290,p=0.017);无癫痫发作的最佳阈值对应切除程度81%;切除程度>81%的患者无癫痫发作率显著更高(OR 2.16,p=0.048)。

关键数值与推荐

  • Meta分析汇总1年Engel IA级无癫痫发作率73%,Engel I级78%。
  • Meta分析汇总末次随访Engel IA级无癫痫发作率60%,Engel I级79%。
  • 本机构分析中无癫痫发作的最佳切除程度阈值为81%。
  • 本机构分析中切除程度>81%与无癫痫发作率显著更高相关(OR 2.16,p=0.048)。

临床怎么用

  • 作者认为最大安全切除可在手术并发症极少的情况下实施,以获得较好的短期和长期无癫痫发作率。
  • 作者认为当无法实现全切除时,切除程度>81%对实现无癫痫发作具有最大的敏感度和特异度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gliomas arising from the insular cortex can be epileptogenic, with a significant proportion of patients having medically refractory epilepsy. The impact of surgery on seizure control for such tumors is not well established. In this study, the authors aimed to investigate seizure outcomes after resection of insular gliomas using a meta-analysis and institutional experience. METHODS: Three databases (Ovid MEDLINE, Embase, and Cochrane Central Register of Controlled Trials) were systematically searched for published studies of seizure outcomes after insular glioma resection from database inception to March 27, 2021. In addition, data were retrospectively collected on all adults (age > 17 years) who had undergone insular glioma resection between June 1997 and June 2015 at the authors' institution. Primary outcome measures were seizure freedom rates at 1 year and the last follow-up. Secondary outcome measures consisted of persistent postoperative neurological deficit beyond 90 days, mortality, and tumor progression or recurrence. RESULTS: Eight studies reporting on 453 patients who had undergone 460 operations were included in the meta-analysis. The pooled mean age of the patients was 42 years. The pooled percentages of patients with extents of resection (EORs) ≥ 90%, 70%-89%, and < 70% were 55%, 33%, and 11%, respectively. The pooled seizure freedom rate at 1 year was 73% for Engel class IA and 78% for Engel class I. The pooled seizure freedom rate at the last follow-up was 60% for Engel class IA and 79% for Engel class I. The pooled percentage of persistent neurological deficit beyond 90 days was 3%. At the authors' institution, 109 patients had undergone resection of insular glioma. A greater EOR was the only significant independent predictor of seizure freedom after surgery (HR 0.290, p = 0.017). The optimal threshold for seizure freedom corresponded to an EOR of 81%. Patients with an EOR > 81% had a significantly higher seizure freedom rate (OR 2.16, p = 0.048). CONCLUSIONS: Maximal safe resection can be performed with minimal surgical morbidity to achieve favorable seizure freedom rates in both the short and long term. When gross-total resection is not possible, an EOR > 81% confers the greatest sensitivity and specificity for achieving seizure freedom. Systematic review registration no.: CRD42021249404 (https://www.crd.york.ac.uk/prospero/).

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Zhang JJY, Lee KS, Wang DD, et al. Seizure outcome after resection of insular glioma: a systematic review, meta-analysis, and institutional experience. J Neurosurg. 2022. PMID: 36242570. doi:10.3171/2022.8.JNS221067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。